Novo Nordisk submitted a higher‑dose formulation of its GLP‑1 obesity drug Wegovy to the FDA and used a priority review voucher to expedite regulatory review. The filing indicates Novo’s push to expand the commercial utility and clinical positioning of its semaglutide franchise amid intensified regulatory and pricing scrutiny. Separately, Novo reported phase II data for amycretin, a dual amylin/GLP‑1 agent, showing a mean weight reduction of 14.5% at 36 weeks in type 2 diabetes patients alongside improved glycemic control. The mid‑stage results strengthen the company’s metabolic pipeline and underline continued investment in next‑generation weight‑loss therapeutics. Both moves signal Novo’s strategy to broaden its product dosing and modality options as competition intensifies in the obesity and diabetes markets and as payors wrestle with coverage decisions around GLP‑1 and next‑gen agents.